Deborah Schrag

66.2k total citations · 21 hit papers
439 papers, 38.7k citations indexed

About

Deborah Schrag is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Deborah Schrag has authored 439 papers receiving a total of 38.7k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Oncology, 108 papers in Economics and Econometrics and 98 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Deborah Schrag's work include Economic and Financial Impacts of Cancer (75 papers), Colorectal Cancer Surgical Treatments (68 papers) and Colorectal Cancer Screening and Detection (68 papers). Deborah Schrag is often cited by papers focused on Economic and Financial Impacts of Cancer (75 papers), Colorectal Cancer Surgical Treatments (68 papers) and Colorectal Cancer Screening and Detection (68 papers). Deborah Schrag collaborates with scholars based in United States, Canada and United Kingdom. Deborah Schrag's co-authors include Peter B. Bach, Joan L. Warren, Leah H. Biller, Katherine S. Panageas, Alexia Iasonos, Colin B. Begg, Ganesh V. Raj, Carrie N. Klabunde, Gerald F. Riley and Ethan Basch and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Deborah Schrag

419 papers receiving 37.9k citations

Hit Papers

How To Build and Interpret a Nomogram for Cancer Prognosis 2001 2026 2009 2017 2008 2015 2021 2002 2004 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. How To Build and Interpret a Nomogram for Cancer Prognosis
    2008 2.3k citations Deborah Schrag, Katherine S. Panageas et al. Journal of Clinical Oncology profile →
  2. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
    2015 1.7k citations Ethan Basch, Clifford A. Hudis et al. Journal of Clinical Oncology profile →
  3. Diagnosis and Treatment of Metastatic Colorectal Cancer
    2021 1.6k citations Deborah Schrag et al. profile →
  4. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.
    2002 1.6k citations Joan L. Warren, Deborah Schrag et al. PubMed profile →
  5. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
    2004 1.1k citations Deborah Schrag et al. Journal of Clinical Oncology profile →
  6. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
    2005 848 citations Deborah Schrag, Leonard B. Saltz et al. Journal of Clinical Oncology profile →
  7. Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
    2012 832 citations Jane C. Weeks, Angel M. Cronin et al. profile →
  8. The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
    2013 828 citations S. Yousuf Zafar, Deborah Schrag et al. The Oncologist profile →
  9. Primary Care Physicians Who Treat Blacks and Whites
    2004 791 citations Deborah Schrag et al. profile →
  10. Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment
    2005 774 citations Deborah Schrag, Joan L. Warren et al. JNCI Journal of the National Cancer Institute profile →
  11. Overview of the SEER-Medicare Data
    2002 713 citations Joan L. Warren, Deborah Schrag et al. profile →
  12. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
    2010 679 citations Deborah Schrag, Eileen M. O’Reilly et al. Journal of Clinical Oncology profile →
  13. Variations in Morbidity after Radical Prostatectomy
    2002 617 citations Deborah Schrag, Joan L. Warren et al. profile →
  14. The Influence of Hospital Volume on Survival after Resection for Lung Cancer
    2001 552 citations Deborah Schrag et al. profile →
  15. American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
    2009 482 citations Deborah Schrag et al. Journal of Clinical Oncology profile →
  16. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
    2009 480 citations Ethan Basch, Laura Sit et al. JNCI Journal of the National Cancer Institute profile →
  17. Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
    2014 421 citations Hajime Uno, Deborah Schrag et al. Journal of Clinical Oncology profile →
  18. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
    2017 344 citations Charles S. Fuchs, Hajime Uno et al. Journal of Clinical Oncology profile →
  19. Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies
    2017 266 citations Deborah Schrag et al. JNCI Journal of the National Cancer Institute profile →
  20. Outcomes of Prognostic Disclosure: Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer
    2015 259 citations Andrea C. Enzinger, Deborah Schrag et al. Journal of Clinical Oncology profile →
  21. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study
    2023 168 citations Deborah Schrag, Charles H. McDonnell et al. profile →

Peers

Deborah Schrag
Eric J. Feuer United States
Angela B. Mariotto United States
Alfred I. Neugut United States
Gary H. Lyman United States
J.W.W. Coebergh Netherlands
Dawn L. Hershman United States
Robert A. Smith United States
Clifford Y. Ko United States
Richard D. Gelber United States
David Osoba Canada
Eric J. Feuer United States
Deborah Schrag
Citations per year, relative to Deborah Schrag Deborah Schrag (= 1×) peers Eric J. Feuer

Countries citing papers authored by Deborah Schrag

Since Specialization
Citations

This map shows the geographic impact of Deborah Schrag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Schrag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Schrag more than expected).

Fields of papers citing papers by Deborah Schrag

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Schrag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Schrag. The network helps show where Deborah Schrag may publish in the future.

Co-authorship network of co-authors of Deborah Schrag

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Schrag. A scholar is included among the top collaborators of Deborah Schrag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Schrag. Deborah Schrag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marinac, Catherine R., Charles H. McDonnell, Lincoln Nadauld, et al.. (2025). Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study. Cancer Prevention Research. 18(8). 475–483.
2.
Winer, Eric P., Laura A. Levit, Ethan Basch, et al.. (2025). Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers. Journal of Clinical Oncology. 43(17). 2017–2023. 2 indexed citations
3.
Enzinger, Andrea C., Hajime Uno, Christine Cronin, et al.. (2024). Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial. JNCI Journal of the National Cancer Institute. 116(7). 1137–1144. 3 indexed citations
4.
Kehl, Kenneth L., Jessica A. Lavery, Samantha Brown, et al.. (2024). Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-Cancer Clinicogenomic Data Set. JCO Precision Oncology. 8(8). e2300489–e2300489. 1 indexed citations
5.
Weiser, Martin R., Qian Shi, George J. Chang, et al.. (2023). 597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance). Annals of Oncology. 34. S431–S432. 1 indexed citations
6.
Adeyemi, Oluwaseun, Allison M. Cuthel, Abraham A. Brody, et al.. (2023). Engagement, Advance Care Planning, and Hospice Use in a Telephonic Nurse-Led Palliative Care Program for Persons Living with Advanced Cancer. Cancers. 15(8). 2310–2310. 2 indexed citations
7.
Kehl, Kenneth L., Hajime Uno, Alexander Gusev, et al.. (2023). Elucidating Analytic Bias Due to Informative Cohort Entry in Cancer Clinico-genomic Datasets. Cancer Epidemiology Biomarkers & Prevention. 32(3). 344–352. 1 indexed citations
8.
Young, Jessica C., et al.. (2022). Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA‐2 trial. Pharmacoepidemiology and Drug Safety. 32(4). 426–434. 3 indexed citations
9.
Kehl, Kenneth L., Stefan Groha, Eva M. Lepisto, et al.. (2021). Clinical Inflection Point Detection on the Basis of EHR Data to Identify Clinical Trial–Ready Patients With Cancer. JCO Clinical Cancer Informatics. 5(5). 622–630. 12 indexed citations
10.
Schrag, Deborah & William H. Redd. (2018). Plenary Abstracts. Psycho-Oncology. 27(S3). 3–7. 1 indexed citations
11.
Schoen, Martin W., Ethan Basch, Lori L. Hudson, et al.. (2018). Software for Administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Human Factors. 5(3). e10070–e10070. 19 indexed citations
12.
Lee, Kyu Ha, Francesca Dominici, Deborah Schrag, & Sebastien Haneuse. (2017). Hierarchical Models for Semicompeting Risks Data With Application to Quality of End-of-Life Care for Pancreatic Cancer. Figshare. 20 indexed citations
13.
Schwartzberg, Lee S., Edward S. Kim, David Liu, & Deborah Schrag. (2017). Precision Oncology: Who, How, What, When, and When Not?. American Society of Clinical Oncology Educational Book. 37(37). 160–169. 166 indexed citations
14.
Lathan, Christopher S., Angel M. Cronin, Reginald Tucker‐Seeley, et al.. (2016). Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. Journal of Clinical Oncology. 34(15). 1732–1740. 294 indexed citations
15.
Wolpin, Brian M., Douglas A. Rubinson, Xiaoxu Wang, et al.. (2014). Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. The Oncologist. 19(6). 637–638. 289 indexed citations
16.
Brooks, Gabriel A., Thomas A. Abrams, Jeffrey A. Meyerhardt, et al.. (2014). Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer. Journal of Clinical Oncology. 32(6). 496–503. 120 indexed citations
17.
Wolpin, Brian M., Kimmie Ng, Andrew X. Zhu, et al.. (2013). Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. The Oncologist. 18(4). 377–378. 38 indexed citations
18.
Sanoff, Hanna K., William R. Carpenter, Til Stürmer‎, et al.. (2012). Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. Journal of Clinical Oncology. 30(21). 2624–2634. 181 indexed citations
19.
Cronin, A., Jane C. Weeks, Elizabeth A. Chrischilles, et al.. (2012). Patient Beliefs About Palliative Radiation Therapy (RT) in Incurable Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 84(3). S1–S1. 1 indexed citations
20.
Schrag, Deborah, Beth A Virnig, & Joan L. Warren. (2009). Linking tumor registry and Medicaid claims to evaluate cancer care delivery.. PubMed. 30(4). 61–73. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eric J. Feuer Breakdown of academic impact, for papers by Angela B. Mariotto Breakdown of academic impact, for papers by Alfred I. Neugut Breakdown of academic impact, for papers by Gary H. Lyman Breakdown of academic impact, for papers by J.W.W. Coebergh Breakdown of academic impact, for papers by Dawn L. Hershman Breakdown of academic impact, for papers by Robert A. Smith Breakdown of academic impact, for papers by Clifford Y. Ko Breakdown of academic impact, for papers by Richard D. Gelber Breakdown of academic impact, for papers by David Osoba
Rankless by CCL
2026